X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (255) 255
humans (252) 252
oncology (191) 191
azd6244 arry-142886 (167) 167
animals (107) 107
cancer (98) 98
cell line, tumor (86) 86
melanoma (83) 83
azd6244 (80) 80
mutation (80) 80
female (78) 78
protein kinase inhibitors - pharmacology (70) 70
mice (61) 61
inhibitor azd6244 arry-142886 (59) 59
open-label (59) 59
selumetinib (59) 59
signal transduction - drug effects (59) 59
phase-ii (57) 57
male (56) 56
apoptosis (54) 54
antineoplastic agents - pharmacology (53) 53
article (53) 53
mek (53) 53
melanoma - drug therapy (51) 51
benzimidazoles - pharmacology (50) 50
braf (49) 49
map kinase signaling system - drug effects (49) 49
activation (47) 47
protein kinase inhibitors - therapeutic use (47) 47
pharmacology & pharmacy (46) 46
cell proliferation - drug effects (45) 45
cell biology (44) 44
kinases (44) 44
mitogen-activated protein kinase kinases - antagonists & inhibitors (44) 44
xenograft model antitumor assays (43) 43
antineoplastic agents - therapeutic use (42) 42
mek inhibitor (42) 42
tumors (42) 42
neoplasms - drug therapy (41) 41
proto-oncogene proteins b-raf - genetics (41) 41
b-raf (40) 40
middle aged (40) 40
research (40) 40
acquired-resistance (39) 39
apoptosis - drug effects (39) 39
in-vivo (39) 39
mutations (39) 39
map kinase kinase 1 - antagonists & inhibitors (38) 38
care and treatment (37) 37
metastatic melanoma (36) 36
aged (35) 35
melanoma - genetics (35) 35
pathway (35) 35
benzimidazoles - administration & dosage (34) 34
resistance (34) 34
signal-regulated kinase (34) 34
oral mek inhibitor (33) 33
cell lung-cancer (32) 32
growth (32) 32
phase-i (32) 32
chemotherapy (31) 31
phosphorylation (31) 31
selumetinib azd6244 (31) 31
adult (30) 30
arry-142886 (30) 30
biochemistry & molecular biology (30) 30
proteins (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
kras (28) 28
map kinase kinase kinases - antagonists & inhibitors (28) 28
ras (28) 28
health aspects (27) 27
kinase kinase-1/2 inhibitor (27) 27
mice, nude (27) 27
molecular targeted therapy (27) 27
protein kinase inhibitors - administration & dosage (27) 27
signal transduction (27) 27
targeted therapy (27) 27
lung cancer (26) 26
map kinase kinase 2 - antagonists & inhibitors (26) 26
melanoma - pathology (26) 26
neoplasms (26) 26
antitumor-activity (25) 25
genetic aspects (25) 25
proto-oncogene proteins c-akt - metabolism (25) 25
therapy (25) 25
treatment outcome (25) 25
analysis (24) 24
benzimidazoles - therapeutic use (24) 24
carcinoma, non-small-cell lung - drug therapy (24) 24
cells (24) 24
drug synergism (24) 24
drug therapy (24) 24
extracellular signal-regulated map kinases - antagonists & inhibitors (24) 24
extracellular signal-regulated map kinases - metabolism (24) 24
lung neoplasms - drug therapy (24) 24
ras proteins - genetics (24) 24
colorectal neoplasms - drug therapy (23) 23
combination (23) 23
drug resistance, neoplasm (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


MOLECULAR CANCER THERAPEUTICS, ISSN 1535-7163, 03/2011, Volume 10, Issue 3, pp. 385 - 394
The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is frequently mutated in human cancer. This pathway consists of... 
CPG ISLAND METHYLATION | SERRATED ADENOMAS | ONCOLOGY | BRAF MUTATION | MELANOCORTIN-1 RECEPTOR | NECROSIS-FACTOR-ALPHA | B-RAF | MC1R VARIANTS | RET/PTC REARRANGEMENTS | AZD6244 ARRY-142886 | DEPENDENT ACTIVATION
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 05/2012, Volume 55, Issue 10, pp. 4594 - 4604
Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered.... 
POTENT | CHEMISTRY, MEDICINAL | RECOGNITION | PATHWAY | RAF | AZD6244 ARRY-142886 | HYDROGEN-BONDS
Journal Article
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 03/2018, Volume 14, Issue 3, pp. 317 - 330
Introduction: Malignant melanoma (MM) is an aggressive disease with a rapidly rising incidence due to neoplasm of melanocytes. Molecular targeted therapies... 
MAPK pathway | Cobimetinib | MEK | Selumetinib | Binimetinib | Melanoma | Pimasertib | systematic review | Trametinib | EFFICACY | SELUMETINIB AZD6244 | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-II | OPEN-LABEL | METASTATIC MELANOMA | NRAS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TOXICOLOGY | AZD6244 ARRY-142886 | BRAF-MUTANT MELANOMA | Index Medicus
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 09/2015, Volume 16, Issue 9, pp. 22976 - 22988
Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase... 
Mitogen-activated protein kinase | MEK | Phosphatidylinositol 3-kinase | Drug resistance | Colorectal cancer | colorectal cancer | SELUMETINIB AZD6244 | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PIK3CA MUTATION | KINASE INHIBITORS | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | mitogen-activated protein kinase | K-RAS | RESISTANCE | drug resistance | AZD6244 ARRY-142886 | TUMOR-GROWTH | PHASE-I | phosphatidylinositol 3-kinase | TOR Serine-Threonine Kinases - metabolism | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Proto-Oncogene Proteins p21(ras) - genetics | Rectum - pathology | Colorectal Neoplasms - genetics | Humans | Colon - drug effects | Molecular Targeted Therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Mitogen-Activated Protein Kinase Kinases - metabolism | Rectum - drug effects | Colorectal Neoplasms - drug therapy | Phosphatidylinositol 3-Kinase - metabolism | Colorectal Neoplasms - metabolism | Colon - pathology | Rectum - metabolism | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Colon - metabolism | Animals | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Protein Kinase Inhibitors - pharmacology | Mutation | Colorectal Neoplasms - pathology | Proteins | Genetics | Kinases
Journal Article
International Journal of Oncology, ISSN 1019-6439, 07/2011, Volume 39, Issue 1, pp. 23 - 31
The MAPK pathway is one of the most important pathways for novel anticancer drug development. We performed high-throughput screening for compounds that induce... 
JTP-74057 | Antitumor activity | MEK | GSK1120212 | PI3K/Akt | HISTONE DEACETYLASE INHIBITOR | KINASE PATHWAY | PANCREATIC-CANCER | CYCLE ARREST | BRAF | COMBINATION | BREAST | GENE | ONCOLOGY | antitumor activity | MUTATIONS | AZD6244 ARRY-142886
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 12/2016, Volume 27, Issue 12, pp. 2210 - 2215
Journal Article
MOLECULAR CANCER THERAPEUTICS, ISSN 1535-7163, 06/2013, Volume 12, Issue 6, pp. 853 - 864
Although mitogen-activated protein (MAP)-extracellular signal-regulated kinase (ERK) kinase (MEK) inhibition is predicted to cause cell death by stabilization... 
PREDICTIVE MARKERS | BREAST-CANCER | IN-VITRO | GROWTH INHIBITION | ONCOLOGY | SELUMETINIB AZD6244 | ACQUIRED-RESISTANCE | OVARIAN-CANCER | ERK ACTIVATION | BCL-2 FAMILY | NAVITOCLAX
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 38 - 47
Journal Article
Journal of Hepatology, ISSN 0168-8278, 11/2018, Volume 69, Issue 5, pp. 1057 - 1065
Treatment of liver cancer remains challenging because of a paucity of drugs that target critical dependencies. Sorafenib is a multikinase inhibitor that is... 
Hepatocellular carcinoma | CRISPR screen | MAPK1 | Sorafenib | ACTIVATED PROTEIN-KINASE | PHASE IB | AZD6244 | ARRY-142886 | REFAMETINIB BAY 86-9766 | COLON-CANCER | HEPATOCELLULAR-CARCINOMA | RESISTANCE | GASTROENTEROLOGY & HEPATOLOGY
Journal Article